This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsCeladon Pharmaceuticals（CEL）株式概要セラドン・ファーマシューティカルズ社は、大麻ベースの医薬品の研究、栽培、製造、販売に従事している。 詳細CEL ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長0/6過去の実績0/6財務の健全性2/6配当金0/6報酬過去 1 年間で収益は519%増加しましたリスク分析収益が 100 万ドル未満 ( £130K )UK市場と比較して、過去 3 か月間の株価の変動が非常に大きい最新の財務報告は6か月以上前のものである 意味のある時価総額がありません ( £9M )すべてのリスクチェックを見るCEL Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUK£Current PriceUK£0.133.0k% 割高 内在価値ディスカウントEst. Revenue$PastFuture-16m130k2016201920222025202620282031Revenue UK£130.0kEarnings UK£19.1kAdvancedSet Fair ValueView all narrativesCeladon Pharmaceuticals Plc 競合他社IncantheraSymbol: OFEX:INCMarket cap: UK£1.7mPoolbeg PharmaSymbol: AIM:POLBMarket cap: UK£35.5mThalia TherapeuticsSymbol: AIM:THATMarket cap: UK£5.4mSareum HoldingsSymbol: AIM:SARMarket cap: UK£28.4m価格と性能株価の高値、安値、推移の概要Celadon Pharmaceuticals過去の株価現在の株価UK£0.1352週高値UK£0.6052週安値UK£0.022ベータ0.191ヶ月の変化0%3ヶ月変化197.78%1年変化-74.52%3年間の変化-83.35%5年間の変化n/aIPOからの変化-90.76%最新ニュースお知らせ • Jul 03Celadon to Seek Approval for De-Listing from London's AIMCeladon Pharmaceuticals Plc intends to seek shareholder approval for the cancellation of its shares trading on London's AIM market and the re-registration of the firm as a a private limited company. Says the cancellation would take effect from August 8, and sets a general meeting for July 28 to seek approval. In a circular sent out ahead of the meeting, Celadon says reasons for the cancellation include stronger access to capital, listing and compliance costs, as well as public market undervaluation. "The chief executive officer believes that the public markets are not fairly valuing the company, and the [CEO] does not believe that this disconnect will change in the short-to-medium term," Celadon explains.お知らせ • Jul 02Celadon Pharmaceuticals Intends to Proceed with DelistingCeladon Pharmaceuticals Plc provided an update on its funding position. Further to the 30 June 2025 announcement, the Board wishes to confirm receipt of the £1.0 million of new funds under the Secured Facilities. As the funds have now been received, the Company intends to proceed with a delisting and a further announcement on this will be made in due course.お知らせ • Jun 09Celadon Pharmaceuticals Plc, Annual General Meeting, Jun 30, 2025Celadon Pharmaceuticals Plc, Annual General Meeting, Jun 30, 2025. Location: the aston tavern hotel, 10 aston hall road, birmingham b6 7ff United Kingdomお知らせ • Mar 25Celadon Pharmaceutical's Board Propose to Delist the Company's Ordinary Shares from AIMOn 19 March 2025, James Short, Chief Executive Officer and 39.5% shareholder of Celadon Pharmaceuticals Plc, informed the Board of an intention to propose resolutions at the next general meeting of Celadon to remove the 4 non-executive directors and Chairman of the Company as directors. The action of Mr. Short was motivated by a desire for the Board to propose a de-listing of the Company from AIM, as Mr. Short believes it will help the Group to significantly reduce its operational costs and also enable the Company to more easily access capital, and on more attractive terms, as an unlisted company. The Board up to 19 March 2025 had not been supportive of the de-listing proposal. Following the Board changes, the Company will proceed with proposing the cancellation of trading of the Company's ordinary shares of £0.01 each ("Ordinary Shares") on AIM (the "Cancellation") via a general meeting. In the event that the Cancellation is approved by shareholders, the Company will make arrangements for a Matched Bargain Facility to assist Shareholders to trade in the Ordinary Shares. The Matched Bargain Facility is anticipated to be provided by J P Jenkins. A circular with further details will be sent to shareholders in due course. Mr. Anton intends to review his position as Chairman of the Company following the result of the Cancellation general meeting. In the event that the Cancellation is approved, Mr. Anton anticipates he will resign from the board.New Risk • Mar 24New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: UK£6.88m (US$8.90m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (35% average weekly change). Earnings have declined by 31% per year over the past 5 years. Revenue is less than US$1m (UK£130k revenue, or US$168k). Market cap is less than US$10m (UK£6.88m market cap, or US$8.90m).お知らせ • Mar 24Celadon Pharmaceuticals plc Announces Board ResignationsCeladon Pharmaceuticals Plc informed the Board of an intention to propose resolutions at the next general meeting of Celadon to remove the 4 non-executive directors and Chairman of the Company as directors. The action of Mr. Short was motivated by a desire for the Board to propose a de-listing of the Company from AIM, as Mr. Short believes it will help the Group to significantly reduce its operational costs and also enable the Company to more easily access capital, and on more attractive terms, as an unlisted company. The Board up to 19 March 2025 had not been supportive of the de-listing proposal. Following discussions, on 21 March 2025 Mr. Robert Barr, Elizabeth Shanahan, David Firth and Dr Steven Hajioff all tendered their resignations as Non-Executive Directors of the Company with immediate effect. Alongside the resignations, Mr. Short withdrew his intention to propose resolutions. Mr. Anton intends to review his position as Chairman of the Company following the result of the Cancellation general meeting. In the event that the Cancellation is approved, Mr. Anton anticipates he will resign from the board.最新情報をもっと見るRecent updatesお知らせ • Jul 03Celadon to Seek Approval for De-Listing from London's AIMCeladon Pharmaceuticals Plc intends to seek shareholder approval for the cancellation of its shares trading on London's AIM market and the re-registration of the firm as a a private limited company. Says the cancellation would take effect from August 8, and sets a general meeting for July 28 to seek approval. In a circular sent out ahead of the meeting, Celadon says reasons for the cancellation include stronger access to capital, listing and compliance costs, as well as public market undervaluation. "The chief executive officer believes that the public markets are not fairly valuing the company, and the [CEO] does not believe that this disconnect will change in the short-to-medium term," Celadon explains.お知らせ • Jul 02Celadon Pharmaceuticals Intends to Proceed with DelistingCeladon Pharmaceuticals Plc provided an update on its funding position. Further to the 30 June 2025 announcement, the Board wishes to confirm receipt of the £1.0 million of new funds under the Secured Facilities. As the funds have now been received, the Company intends to proceed with a delisting and a further announcement on this will be made in due course.お知らせ • Jun 09Celadon Pharmaceuticals Plc, Annual General Meeting, Jun 30, 2025Celadon Pharmaceuticals Plc, Annual General Meeting, Jun 30, 2025. Location: the aston tavern hotel, 10 aston hall road, birmingham b6 7ff United Kingdomお知らせ • Mar 25Celadon Pharmaceutical's Board Propose to Delist the Company's Ordinary Shares from AIMOn 19 March 2025, James Short, Chief Executive Officer and 39.5% shareholder of Celadon Pharmaceuticals Plc, informed the Board of an intention to propose resolutions at the next general meeting of Celadon to remove the 4 non-executive directors and Chairman of the Company as directors. The action of Mr. Short was motivated by a desire for the Board to propose a de-listing of the Company from AIM, as Mr. Short believes it will help the Group to significantly reduce its operational costs and also enable the Company to more easily access capital, and on more attractive terms, as an unlisted company. The Board up to 19 March 2025 had not been supportive of the de-listing proposal. Following the Board changes, the Company will proceed with proposing the cancellation of trading of the Company's ordinary shares of £0.01 each ("Ordinary Shares") on AIM (the "Cancellation") via a general meeting. In the event that the Cancellation is approved by shareholders, the Company will make arrangements for a Matched Bargain Facility to assist Shareholders to trade in the Ordinary Shares. The Matched Bargain Facility is anticipated to be provided by J P Jenkins. A circular with further details will be sent to shareholders in due course. Mr. Anton intends to review his position as Chairman of the Company following the result of the Cancellation general meeting. In the event that the Cancellation is approved, Mr. Anton anticipates he will resign from the board.New Risk • Mar 24New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: UK£6.88m (US$8.90m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (35% average weekly change). Earnings have declined by 31% per year over the past 5 years. Revenue is less than US$1m (UK£130k revenue, or US$168k). Market cap is less than US$10m (UK£6.88m market cap, or US$8.90m).お知らせ • Mar 24Celadon Pharmaceuticals plc Announces Board ResignationsCeladon Pharmaceuticals Plc informed the Board of an intention to propose resolutions at the next general meeting of Celadon to remove the 4 non-executive directors and Chairman of the Company as directors. The action of Mr. Short was motivated by a desire for the Board to propose a de-listing of the Company from AIM, as Mr. Short believes it will help the Group to significantly reduce its operational costs and also enable the Company to more easily access capital, and on more attractive terms, as an unlisted company. The Board up to 19 March 2025 had not been supportive of the de-listing proposal. Following discussions, on 21 March 2025 Mr. Robert Barr, Elizabeth Shanahan, David Firth and Dr Steven Hajioff all tendered their resignations as Non-Executive Directors of the Company with immediate effect. Alongside the resignations, Mr. Short withdrew his intention to propose resolutions. Mr. Anton intends to review his position as Chairman of the Company following the result of the Cancellation general meeting. In the event that the Cancellation is approved, Mr. Anton anticipates he will resign from the board.Reported Earnings • Oct 02First half 2024 earnings released: UK£0.037 loss per share (vs UK£0.07 loss in 1H 2023)First half 2024 results: UK£0.037 loss per share (improved from UK£0.07 loss in 1H 2023). Net loss: UK£2.39m (loss narrowed 44% from 1H 2023).お知らせ • Sep 30Celadon Pharmaceuticals Plc Announces Departure of Jonathan Turner, Chief Financial Officer, Effective 27 December 2024The Board of Celadon Pharmaceuticals Plc announced that Mr. Jonathan Turner, Chief Financial Officer, will leave his position on the Board on 27 December 2024. The Company will be starting the search for Mr. Turner's successor imminently and will provide a further update when a new candidate has been appointed.New Risk • Aug 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£6.3m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 46% per year over the past 5 years. Revenue is less than US$1m (UK£75k revenue, or US$96k). Minor Risks Shareholders have been diluted in the past year (7.0% increase in shares outstanding). Market cap is less than US$100m (UK£18.8m market cap, or US$24.0m).お知らせ • Jun 06Celadon Pharmaceuticals Plc, Annual General Meeting, Jun 27, 2024Celadon Pharmaceuticals Plc, Annual General Meeting, Jun 27, 2024. Location: the offices of gowling wlg uk llp, 4 more london riverside, se1 2au, london United KingdomReported Earnings • May 15Full year 2023 earnings released: UK£0.12 loss per share (vs UK£0.29 loss in FY 2022)Full year 2023 results: UK£0.12 loss per share (improved from UK£0.29 loss in FY 2022). Net loss: UK£7.14m (loss narrowed 58% from FY 2022).New Risk • Apr 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 69% per year over the past 5 years. Revenue is less than US$1m (UK£21k revenue, or US$26k). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (4.1% increase in shares outstanding). Market cap is less than US$100m (UK£61.0m market cap, or US$75.9m).お知らせ • Mar 09Celadon Pharmaceuticals plc Announces the Results of an Early Economic Analysis of the Data Collected as Part of the Feasibility Study for Its Fully Approved Chronic Pain Clinical TrialCeladon Pharmaceuticals Plc announced the results of an early economic analysis of the data collected as part of the feasibility study for its fully approved chronic pain clinical trial. The analysis was undertaken by York Health Economic Consulting which provides consultancy and research services in health economics. The findings of YHEC's analysis are as follows: Patients on the feasibility study recorded an almost 50% (49.6%) reduction in pain scores in the first month of using cannabis-based medicines, with this reduction in pain being sustained throughout the three-month study. Patients saw a significant improvement in their mean quality of sleep scores of 1.6 points (p=0.01) and a reduction in the use of opioids and associated medicines. When assessed using the economic framework recommended by NICE, adding cannabis-based medicines to the Standard of Care was found to deliver a cost-effective solution and, depending on the price point, a cost saving to the National Health Service and Patients' quality-adjusted life years also increased.New Risk • Dec 18New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 4.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 69% per year over the past 5 years. Revenue is less than US$1m (UK£21k revenue, or US$27k). Minor Risks Shareholders have been diluted in the past year (4.1% increase in shares outstanding). Market cap is less than US$100m (UK£73.8m market cap, or US$93.3m).お知らせ • Oct 13Celadon Pharmaceuticals Plc has completed a Follow-on Equity Offering in the amount of £1 million.Celadon Pharmaceuticals Plc has completed a Follow-on Equity Offering in the amount of £1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 800,000 Price\Range: £1.25 Transaction Features: Subsequent Direct ListingReported Earnings • Oct 01First half 2023 earnings released: UK£0.07 loss per share (vs UK£0.25 loss in 1H 2022)First half 2023 results: UK£0.07 loss per share (improved from UK£0.25 loss in 1H 2022). Net loss: UK£4.30m (loss narrowed 68% from 1H 2022).New Risk • Sep 29New major risk - Revenue and earnings growthEarnings have declined by 72% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£7.2m free cash flow). Earnings have declined by 72% per year over the past 5 years. Revenue is less than US$1m (UK£21k revenue, or US$26k). Minor Risk Market cap is less than US$100m (UK£74.0m market cap, or US$90.4m).お知らせ • Sep 18Celadon Pharmaceuticals Plc to Report First Half, 2023 Results on Sep 28, 2023Celadon Pharmaceuticals Plc announced that they will report first half, 2023 results on Sep 28, 2023お知らせ • Aug 03Celadon Pharmaceuticals Plc Receives Approval to Roll-Out Chronic Pain Clinical TrialCeladon Pharmaceuticals Plc has received approval from the National Health Service ("NHS") Research Ethics Committee to roll-out its non-cancer chronic pain clinical trial for up to 5,000 patients (the "Trial"). The Company previously held conditional approval from the Medicines and Healthcare products Regulatory Agency ("MHRA") for the Trial, however before formally commencing the Trial, the NHS's Ethics Committee requested an initial Feasibility Study to be conducted over a three-month period. The results of the Feasibility Study were submitted for review on 30 December 2022 (as announced by the Company) and indicatedpositive outcomes for quality of life, pain and sleep, as well as the reduction of opioid usage. As an approved Trial, it is believed to be the only one of its kind in the UK, and is designed tocreate adata set that will support doctors' prescriptions of cannabis-based medicines, and in time enable potential reimbursement by the NHS and insurance companies. It also enables General Practitioners to prescribe the medicine to patientsin addition to specialist doctors, and organizations such as charities can advertise recruitment for the Trial. The Company believes this to be a major advance in enabling much wider access for patients, ultimately leading to the opening up of the UK market for cannabis-based medicines. The Company is working with its partners to finalise the plan for the optimal and timely roll-out of the Trial.お知らせ • Jun 06Celadon Pharmaceuticals Plc, Annual General Meeting, Jun 29, 2023Celadon Pharmaceuticals Plc, Annual General Meeting, Jun 29, 2023, at 11:00 Coordinated Universal Time. Location: CMS Cameron McKenna Nabarro Olswang LLP, Cannon Place, 78 Cannon Street London United Kingdomお知らせ • May 26Celadon Pharmaceuticals Plc to Report Fiscal Year 2022 Results on Jun 05, 2023Celadon Pharmaceuticals Plc announced that they will report fiscal year 2022 results on Jun 05, 2023お知らせ • Dec 23Celadon Pharmaceuticals Plc Announces Update on Good Manufacturing Practices Registration by UK Medicines and Healthcare Products Regulatory AgencyCeladon Pharmaceuticals Plc provided an update on the application for registration of its West Midlands UK facility with the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the Good Manufacturing Practices (GMP) manufacturing of its cannabis Active Pharmaceutical Ingredient (API). Celadon has successfully made the necessary submissions to the MHRA as part of its GMP registration, having received an MHRA inspection of its facilities during Fourth Quarter 2022. This is in line with the timings provided in the Interim results announced on 29 September 2022. Celadon can confirm that no critical issues were raised by the MHRA during the inspection. As part of the audit, the Company also sent samples of its API to an independent third party for analytical testing. The Company reported that the testing confirmed positive results across all batches, with high-quality, consistent and pharmaceutical-grade API product. Based on the above, Celadon remains confident that the Company will obtain registration from the MHRA for the GMP manufacturing of its cannabis API. The directors anticipate receiving this registration during first quarter 2023.Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Nov 01Celadon Pharmaceuticals Plc Announces CFO ChangesCeladon Pharmaceuticals Plc announced the appointment of Jonathan Turner as Chief Financial Officer of the Group. Jonathan will start a phased transition into his role from November 2022 and will join the Company on a full time basis from February 2023. He will be appointed to the Board at that time. Jonathan succeeds Katie Long who is returning to her role within Tessera Investment Management Limited ("Tessera"), having established and led Celadon's finance function over the previous year and during the Company's AIM IPO. Katie will continue to provide support to the Company through to the commencement of Jonathan's appointment on a full time basis, and will step down from the Board at that time. Jonathan joins from FTSE250 listed Oxford Instruments plc, where he has been Group Director of Accounting, Tax and Treasury since September 2020, and a Divisional Finance Director for the three years before that. During this time, he has worked closely with the Oxford Instruments plc's CFO and has been responsible for internal and external financial reporting, and developing and maintaining financial and operational systems. Prior to this, Jonathan was Group Company Secretary and Head of Tax and Treasury for FTSE listed Synergy Health plc ("Synergy") and Finance Director for NYSE listed STERIS plc, following its acquisition of Synergy. Jonathan is a Chartered Accountant and Associate Member of the Association of Corporate Treasurers and was previously a Senior Manager at EY, where he worked from 2003 until 2010, and originally qualified at Smith & Williamson.お知らせ • Sep 13Celadon Pharmaceuticals Plc to Report First Half, 2022 Results on Sep 29, 2022Celadon Pharmaceuticals Plc announced that they will report first half, 2022 results on Sep 29, 2022Board Change • Aug 31Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Jun 01Celadon Pharmaceuticals Plc, Annual General Meeting, Jun 27, 2022Celadon Pharmaceuticals Plc, Annual General Meeting, Jun 27, 2022, at 15:00 Coordinated Universal Time. Location: Edgbaston Park Hotel and Conference Centre, 53 Edgbaston Park Road Birmingham United Kingdom株主還元CELGB PharmaceuticalsGB 市場7D0%1.6%1.4%1Y-74.5%25.2%19.5%株主還元を見る業界別リターン: CEL過去 1 年間で25.2 % の収益を上げたUK Pharmaceuticals業界を下回りました。リターン対市場: CELは、過去 1 年間で19.5 % のリターンを上げたUK市場を下回りました。価格変動Is CEL's price volatile compared to industry and market?CEL volatilityCEL Average Weekly Movement41.5%Pharmaceuticals Industry Average Movement6.2%Market Average Movement5.8%10% most volatile stocks in GB Market12.0%10% least volatile stocks in GB Market3.1%安定した株価: CELの株価は、 UK市場と比較して過去 3 か月間で変動しています。時間の経過による変動: CELの weekly volatility ( 41% ) は過去 1 年間安定していますが、依然としてUKの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト201827Jim Shortceladonpharma.com/セラドン・ファーマシューティカルズ社は、大麻ベースの医薬品の研究、栽培、製造、販売を行っている。同社は主に、医薬品として使用される大麻を屋内で水耕栽培することに注力している。同社の製品は慢性疼痛や自閉症スペクトラム障害の治療に使用されている。Celadon Pharmaceuticals Plcは2018年に設立され、英国ロンドンに本社を置いている。もっと見るCeladon Pharmaceuticals Plc 基礎のまとめCeladon Pharmaceuticals の収益と売上を時価総額と比較するとどうか。CEL 基礎統計学時価総額UK£9.23m収益（TTM）-UK£5.23m売上高(TTM)UK£130.00k71.0xP/Sレシオ-1.8xPER（株価収益率CEL は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計CEL 損益計算書（TTM）収益UK£130.00k売上原価UK£91.00k売上総利益UK£39.00kその他の費用UK£5.27m収益-UK£5.23m直近の収益報告Jun 30, 2024次回決算日該当なし一株当たり利益（EPS）-0.076グロス・マージン30.00%純利益率-4,024.62%有利子負債／自己資本比率1.3%CEL の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/08/08 07:03終値2025/06/30 00:00収益2024/06/30年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Celadon Pharmaceuticals Plc 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jul 03Celadon to Seek Approval for De-Listing from London's AIMCeladon Pharmaceuticals Plc intends to seek shareholder approval for the cancellation of its shares trading on London's AIM market and the re-registration of the firm as a a private limited company. Says the cancellation would take effect from August 8, and sets a general meeting for July 28 to seek approval. In a circular sent out ahead of the meeting, Celadon says reasons for the cancellation include stronger access to capital, listing and compliance costs, as well as public market undervaluation. "The chief executive officer believes that the public markets are not fairly valuing the company, and the [CEO] does not believe that this disconnect will change in the short-to-medium term," Celadon explains.
お知らせ • Jul 02Celadon Pharmaceuticals Intends to Proceed with DelistingCeladon Pharmaceuticals Plc provided an update on its funding position. Further to the 30 June 2025 announcement, the Board wishes to confirm receipt of the £1.0 million of new funds under the Secured Facilities. As the funds have now been received, the Company intends to proceed with a delisting and a further announcement on this will be made in due course.
お知らせ • Jun 09Celadon Pharmaceuticals Plc, Annual General Meeting, Jun 30, 2025Celadon Pharmaceuticals Plc, Annual General Meeting, Jun 30, 2025. Location: the aston tavern hotel, 10 aston hall road, birmingham b6 7ff United Kingdom
お知らせ • Mar 25Celadon Pharmaceutical's Board Propose to Delist the Company's Ordinary Shares from AIMOn 19 March 2025, James Short, Chief Executive Officer and 39.5% shareholder of Celadon Pharmaceuticals Plc, informed the Board of an intention to propose resolutions at the next general meeting of Celadon to remove the 4 non-executive directors and Chairman of the Company as directors. The action of Mr. Short was motivated by a desire for the Board to propose a de-listing of the Company from AIM, as Mr. Short believes it will help the Group to significantly reduce its operational costs and also enable the Company to more easily access capital, and on more attractive terms, as an unlisted company. The Board up to 19 March 2025 had not been supportive of the de-listing proposal. Following the Board changes, the Company will proceed with proposing the cancellation of trading of the Company's ordinary shares of £0.01 each ("Ordinary Shares") on AIM (the "Cancellation") via a general meeting. In the event that the Cancellation is approved by shareholders, the Company will make arrangements for a Matched Bargain Facility to assist Shareholders to trade in the Ordinary Shares. The Matched Bargain Facility is anticipated to be provided by J P Jenkins. A circular with further details will be sent to shareholders in due course. Mr. Anton intends to review his position as Chairman of the Company following the result of the Cancellation general meeting. In the event that the Cancellation is approved, Mr. Anton anticipates he will resign from the board.
New Risk • Mar 24New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: UK£6.88m (US$8.90m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (35% average weekly change). Earnings have declined by 31% per year over the past 5 years. Revenue is less than US$1m (UK£130k revenue, or US$168k). Market cap is less than US$10m (UK£6.88m market cap, or US$8.90m).
お知らせ • Mar 24Celadon Pharmaceuticals plc Announces Board ResignationsCeladon Pharmaceuticals Plc informed the Board of an intention to propose resolutions at the next general meeting of Celadon to remove the 4 non-executive directors and Chairman of the Company as directors. The action of Mr. Short was motivated by a desire for the Board to propose a de-listing of the Company from AIM, as Mr. Short believes it will help the Group to significantly reduce its operational costs and also enable the Company to more easily access capital, and on more attractive terms, as an unlisted company. The Board up to 19 March 2025 had not been supportive of the de-listing proposal. Following discussions, on 21 March 2025 Mr. Robert Barr, Elizabeth Shanahan, David Firth and Dr Steven Hajioff all tendered their resignations as Non-Executive Directors of the Company with immediate effect. Alongside the resignations, Mr. Short withdrew his intention to propose resolutions. Mr. Anton intends to review his position as Chairman of the Company following the result of the Cancellation general meeting. In the event that the Cancellation is approved, Mr. Anton anticipates he will resign from the board.
お知らせ • Jul 03Celadon to Seek Approval for De-Listing from London's AIMCeladon Pharmaceuticals Plc intends to seek shareholder approval for the cancellation of its shares trading on London's AIM market and the re-registration of the firm as a a private limited company. Says the cancellation would take effect from August 8, and sets a general meeting for July 28 to seek approval. In a circular sent out ahead of the meeting, Celadon says reasons for the cancellation include stronger access to capital, listing and compliance costs, as well as public market undervaluation. "The chief executive officer believes that the public markets are not fairly valuing the company, and the [CEO] does not believe that this disconnect will change in the short-to-medium term," Celadon explains.
お知らせ • Jul 02Celadon Pharmaceuticals Intends to Proceed with DelistingCeladon Pharmaceuticals Plc provided an update on its funding position. Further to the 30 June 2025 announcement, the Board wishes to confirm receipt of the £1.0 million of new funds under the Secured Facilities. As the funds have now been received, the Company intends to proceed with a delisting and a further announcement on this will be made in due course.
お知らせ • Jun 09Celadon Pharmaceuticals Plc, Annual General Meeting, Jun 30, 2025Celadon Pharmaceuticals Plc, Annual General Meeting, Jun 30, 2025. Location: the aston tavern hotel, 10 aston hall road, birmingham b6 7ff United Kingdom
お知らせ • Mar 25Celadon Pharmaceutical's Board Propose to Delist the Company's Ordinary Shares from AIMOn 19 March 2025, James Short, Chief Executive Officer and 39.5% shareholder of Celadon Pharmaceuticals Plc, informed the Board of an intention to propose resolutions at the next general meeting of Celadon to remove the 4 non-executive directors and Chairman of the Company as directors. The action of Mr. Short was motivated by a desire for the Board to propose a de-listing of the Company from AIM, as Mr. Short believes it will help the Group to significantly reduce its operational costs and also enable the Company to more easily access capital, and on more attractive terms, as an unlisted company. The Board up to 19 March 2025 had not been supportive of the de-listing proposal. Following the Board changes, the Company will proceed with proposing the cancellation of trading of the Company's ordinary shares of £0.01 each ("Ordinary Shares") on AIM (the "Cancellation") via a general meeting. In the event that the Cancellation is approved by shareholders, the Company will make arrangements for a Matched Bargain Facility to assist Shareholders to trade in the Ordinary Shares. The Matched Bargain Facility is anticipated to be provided by J P Jenkins. A circular with further details will be sent to shareholders in due course. Mr. Anton intends to review his position as Chairman of the Company following the result of the Cancellation general meeting. In the event that the Cancellation is approved, Mr. Anton anticipates he will resign from the board.
New Risk • Mar 24New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: UK£6.88m (US$8.90m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (35% average weekly change). Earnings have declined by 31% per year over the past 5 years. Revenue is less than US$1m (UK£130k revenue, or US$168k). Market cap is less than US$10m (UK£6.88m market cap, or US$8.90m).
お知らせ • Mar 24Celadon Pharmaceuticals plc Announces Board ResignationsCeladon Pharmaceuticals Plc informed the Board of an intention to propose resolutions at the next general meeting of Celadon to remove the 4 non-executive directors and Chairman of the Company as directors. The action of Mr. Short was motivated by a desire for the Board to propose a de-listing of the Company from AIM, as Mr. Short believes it will help the Group to significantly reduce its operational costs and also enable the Company to more easily access capital, and on more attractive terms, as an unlisted company. The Board up to 19 March 2025 had not been supportive of the de-listing proposal. Following discussions, on 21 March 2025 Mr. Robert Barr, Elizabeth Shanahan, David Firth and Dr Steven Hajioff all tendered their resignations as Non-Executive Directors of the Company with immediate effect. Alongside the resignations, Mr. Short withdrew his intention to propose resolutions. Mr. Anton intends to review his position as Chairman of the Company following the result of the Cancellation general meeting. In the event that the Cancellation is approved, Mr. Anton anticipates he will resign from the board.
Reported Earnings • Oct 02First half 2024 earnings released: UK£0.037 loss per share (vs UK£0.07 loss in 1H 2023)First half 2024 results: UK£0.037 loss per share (improved from UK£0.07 loss in 1H 2023). Net loss: UK£2.39m (loss narrowed 44% from 1H 2023).
お知らせ • Sep 30Celadon Pharmaceuticals Plc Announces Departure of Jonathan Turner, Chief Financial Officer, Effective 27 December 2024The Board of Celadon Pharmaceuticals Plc announced that Mr. Jonathan Turner, Chief Financial Officer, will leave his position on the Board on 27 December 2024. The Company will be starting the search for Mr. Turner's successor imminently and will provide a further update when a new candidate has been appointed.
New Risk • Aug 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£6.3m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 46% per year over the past 5 years. Revenue is less than US$1m (UK£75k revenue, or US$96k). Minor Risks Shareholders have been diluted in the past year (7.0% increase in shares outstanding). Market cap is less than US$100m (UK£18.8m market cap, or US$24.0m).
お知らせ • Jun 06Celadon Pharmaceuticals Plc, Annual General Meeting, Jun 27, 2024Celadon Pharmaceuticals Plc, Annual General Meeting, Jun 27, 2024. Location: the offices of gowling wlg uk llp, 4 more london riverside, se1 2au, london United Kingdom
Reported Earnings • May 15Full year 2023 earnings released: UK£0.12 loss per share (vs UK£0.29 loss in FY 2022)Full year 2023 results: UK£0.12 loss per share (improved from UK£0.29 loss in FY 2022). Net loss: UK£7.14m (loss narrowed 58% from FY 2022).
New Risk • Apr 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 69% per year over the past 5 years. Revenue is less than US$1m (UK£21k revenue, or US$26k). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (4.1% increase in shares outstanding). Market cap is less than US$100m (UK£61.0m market cap, or US$75.9m).
お知らせ • Mar 09Celadon Pharmaceuticals plc Announces the Results of an Early Economic Analysis of the Data Collected as Part of the Feasibility Study for Its Fully Approved Chronic Pain Clinical TrialCeladon Pharmaceuticals Plc announced the results of an early economic analysis of the data collected as part of the feasibility study for its fully approved chronic pain clinical trial. The analysis was undertaken by York Health Economic Consulting which provides consultancy and research services in health economics. The findings of YHEC's analysis are as follows: Patients on the feasibility study recorded an almost 50% (49.6%) reduction in pain scores in the first month of using cannabis-based medicines, with this reduction in pain being sustained throughout the three-month study. Patients saw a significant improvement in their mean quality of sleep scores of 1.6 points (p=0.01) and a reduction in the use of opioids and associated medicines. When assessed using the economic framework recommended by NICE, adding cannabis-based medicines to the Standard of Care was found to deliver a cost-effective solution and, depending on the price point, a cost saving to the National Health Service and Patients' quality-adjusted life years also increased.
New Risk • Dec 18New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 4.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 69% per year over the past 5 years. Revenue is less than US$1m (UK£21k revenue, or US$27k). Minor Risks Shareholders have been diluted in the past year (4.1% increase in shares outstanding). Market cap is less than US$100m (UK£73.8m market cap, or US$93.3m).
お知らせ • Oct 13Celadon Pharmaceuticals Plc has completed a Follow-on Equity Offering in the amount of £1 million.Celadon Pharmaceuticals Plc has completed a Follow-on Equity Offering in the amount of £1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 800,000 Price\Range: £1.25 Transaction Features: Subsequent Direct Listing
Reported Earnings • Oct 01First half 2023 earnings released: UK£0.07 loss per share (vs UK£0.25 loss in 1H 2022)First half 2023 results: UK£0.07 loss per share (improved from UK£0.25 loss in 1H 2022). Net loss: UK£4.30m (loss narrowed 68% from 1H 2022).
New Risk • Sep 29New major risk - Revenue and earnings growthEarnings have declined by 72% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£7.2m free cash flow). Earnings have declined by 72% per year over the past 5 years. Revenue is less than US$1m (UK£21k revenue, or US$26k). Minor Risk Market cap is less than US$100m (UK£74.0m market cap, or US$90.4m).
お知らせ • Sep 18Celadon Pharmaceuticals Plc to Report First Half, 2023 Results on Sep 28, 2023Celadon Pharmaceuticals Plc announced that they will report first half, 2023 results on Sep 28, 2023
お知らせ • Aug 03Celadon Pharmaceuticals Plc Receives Approval to Roll-Out Chronic Pain Clinical TrialCeladon Pharmaceuticals Plc has received approval from the National Health Service ("NHS") Research Ethics Committee to roll-out its non-cancer chronic pain clinical trial for up to 5,000 patients (the "Trial"). The Company previously held conditional approval from the Medicines and Healthcare products Regulatory Agency ("MHRA") for the Trial, however before formally commencing the Trial, the NHS's Ethics Committee requested an initial Feasibility Study to be conducted over a three-month period. The results of the Feasibility Study were submitted for review on 30 December 2022 (as announced by the Company) and indicatedpositive outcomes for quality of life, pain and sleep, as well as the reduction of opioid usage. As an approved Trial, it is believed to be the only one of its kind in the UK, and is designed tocreate adata set that will support doctors' prescriptions of cannabis-based medicines, and in time enable potential reimbursement by the NHS and insurance companies. It also enables General Practitioners to prescribe the medicine to patientsin addition to specialist doctors, and organizations such as charities can advertise recruitment for the Trial. The Company believes this to be a major advance in enabling much wider access for patients, ultimately leading to the opening up of the UK market for cannabis-based medicines. The Company is working with its partners to finalise the plan for the optimal and timely roll-out of the Trial.
お知らせ • Jun 06Celadon Pharmaceuticals Plc, Annual General Meeting, Jun 29, 2023Celadon Pharmaceuticals Plc, Annual General Meeting, Jun 29, 2023, at 11:00 Coordinated Universal Time. Location: CMS Cameron McKenna Nabarro Olswang LLP, Cannon Place, 78 Cannon Street London United Kingdom
お知らせ • May 26Celadon Pharmaceuticals Plc to Report Fiscal Year 2022 Results on Jun 05, 2023Celadon Pharmaceuticals Plc announced that they will report fiscal year 2022 results on Jun 05, 2023
お知らせ • Dec 23Celadon Pharmaceuticals Plc Announces Update on Good Manufacturing Practices Registration by UK Medicines and Healthcare Products Regulatory AgencyCeladon Pharmaceuticals Plc provided an update on the application for registration of its West Midlands UK facility with the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the Good Manufacturing Practices (GMP) manufacturing of its cannabis Active Pharmaceutical Ingredient (API). Celadon has successfully made the necessary submissions to the MHRA as part of its GMP registration, having received an MHRA inspection of its facilities during Fourth Quarter 2022. This is in line with the timings provided in the Interim results announced on 29 September 2022. Celadon can confirm that no critical issues were raised by the MHRA during the inspection. As part of the audit, the Company also sent samples of its API to an independent third party for analytical testing. The Company reported that the testing confirmed positive results across all batches, with high-quality, consistent and pharmaceutical-grade API product. Based on the above, Celadon remains confident that the Company will obtain registration from the MHRA for the GMP manufacturing of its cannabis API. The directors anticipate receiving this registration during first quarter 2023.
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Nov 01Celadon Pharmaceuticals Plc Announces CFO ChangesCeladon Pharmaceuticals Plc announced the appointment of Jonathan Turner as Chief Financial Officer of the Group. Jonathan will start a phased transition into his role from November 2022 and will join the Company on a full time basis from February 2023. He will be appointed to the Board at that time. Jonathan succeeds Katie Long who is returning to her role within Tessera Investment Management Limited ("Tessera"), having established and led Celadon's finance function over the previous year and during the Company's AIM IPO. Katie will continue to provide support to the Company through to the commencement of Jonathan's appointment on a full time basis, and will step down from the Board at that time. Jonathan joins from FTSE250 listed Oxford Instruments plc, where he has been Group Director of Accounting, Tax and Treasury since September 2020, and a Divisional Finance Director for the three years before that. During this time, he has worked closely with the Oxford Instruments plc's CFO and has been responsible for internal and external financial reporting, and developing and maintaining financial and operational systems. Prior to this, Jonathan was Group Company Secretary and Head of Tax and Treasury for FTSE listed Synergy Health plc ("Synergy") and Finance Director for NYSE listed STERIS plc, following its acquisition of Synergy. Jonathan is a Chartered Accountant and Associate Member of the Association of Corporate Treasurers and was previously a Senior Manager at EY, where he worked from 2003 until 2010, and originally qualified at Smith & Williamson.
お知らせ • Sep 13Celadon Pharmaceuticals Plc to Report First Half, 2022 Results on Sep 29, 2022Celadon Pharmaceuticals Plc announced that they will report first half, 2022 results on Sep 29, 2022
Board Change • Aug 31Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Jun 01Celadon Pharmaceuticals Plc, Annual General Meeting, Jun 27, 2022Celadon Pharmaceuticals Plc, Annual General Meeting, Jun 27, 2022, at 15:00 Coordinated Universal Time. Location: Edgbaston Park Hotel and Conference Centre, 53 Edgbaston Park Road Birmingham United Kingdom
